Flick Gocke Schaumburg advised Evestia Clinical on the acquisition of ICRC-Weyer

Flick Gocke Schaumburg has advised Evestia Clinical, a leading independent global specialist Contract Research Organization (CRO), on the acquisition of Berlin-based ICRC-Weyer GmbH.

With the acquisition Evestia Clinical adds further specialist biostatistics, data management, and medical writing expertise to Evestia Clinical's full-service offering and strengthens its presence in Germany and across Europe.

ICRC-Weyer will integrate with Evestia Clinical's operations with no change to its services or teams and it will continue to operate under the ICRC-Weyer brand. 

The parties have agreed not to disclose the financial terms of the transaction.

Advisor to Evestia Clinical: Flick Gocke Schaumburg
Dr. Bettina Wirth-Duncan (Lead; M&A/Private Equity), Matthias Full, Corina Hackbarth (both Private Equity/Tax); Associates: Dr. Julius Simon, Simon Kaiser, Emilia Riedelsheimer (all M&A/Private Equity), Tomke Zeeh, Claudia Lin-Wei Zinnack (both Private Equity/Tax)

Evestia Clinical is a leading global specialist CRO, partnering with biotech companies to accelerate the development of therapies in areas of significant unmet medical need. Backed by Kester Capital, Evestia Clinical is dedicated to advancing healthcare through cutting-edge clinical research. 

Founded in 1993 by Prof. Dr. Geerd Weyer, ICRC-Weyer is a clinical research organization (CRO) supporting companies across all stages of clinical research and development. <<<